What has share price or "differing amounts of shares" got to do with anything?
Viralytics (under the stewardship of Paul Hopper) was taken over by Merck for $A500 million for essentially a single drug - Cavatak.
A number of ex-Viralytics scientists are now working with IMU following its acquisition of Vaxinia from City of Hope.
Imugene has a number of therapies in the development pipeline, not just one. More importantly, a number of these are likely complementary - two drugs may not be effective on their own, but are effective in tandem.
https://www.biospace.com/article/re...pe-a-cancer-centre-in-los-angeles-california/
Is Gilead chief Dan O’Day ready for a new biotech deal in the oncology field?, page-6
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.7¢ |
Change
0.003(6.82%) |
Mkt cap ! $349.6M | |||
| Open | High | Low | Value | Volume |
| 4.7¢ | 4.9¢ | 4.5¢ | $963.9K | 20.44M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 1558493 | 4.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.7¢ | 1495843 | 7 |
View Market Depth
| Last trade - 16.10pm 05/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |